Intellia Therapeutics, Inc.NTLANASDAQ
Loading
Year-over-year operating income growth rate
Latest
11.45%
↑ 222% vs avg
Percentile
P87
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-9.41%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 11.45% |
| Q3 2025 | -1.35% |
| Q2 2025 | 8.95% |
| Q1 2025 | 11.46% |
| Q4 2024 | 5.75% |
| Q3 2024 | -4.12% |
| Q2 2024 | -21.96% |
| Q1 2024 | 18.51% |
| Q4 2023 | -6.70% |
| Q3 2023 | 0.93% |
| Q2 2023 | -18.20% |
| Q1 2023 | -1.70% |
| Q4 2022 | -4.32% |
| Q3 2022 | -7.35% |
| Q2 2022 | 31.85% |
| Q1 2022 | -79.38% |
| Q4 2021 | -11.70% |
| Q3 2021 | -4.31% |
| Q2 2021 | -48.66% |
| Q1 2021 | -9.50% |
| Q4 2020 | -50.88% |
| Q3 2020 | 14.93% |
| Q2 2020 | 0.04% |
| Q1 2020 | -11.01% |
| Q4 2019 | -17.54% |
| Q3 2019 | 7.76% |
| Q2 2019 | -15.33% |
| Q1 2019 | -14.76% |
| Q4 2018 | 13.91% |
| Q3 2018 | -2.14% |
| Q2 2018 | -5.19% |
| Q1 2018 | 9.25% |
| Q4 2017 | -55.69% |
| Q3 2017 | 0.89% |
| Q2 2017 | -23.70% |
| Q1 2017 | -19.65% |
| Q4 2016 | -40.60% |
| Q3 2016 | -10.81% |
| Q2 2016 | -3.76% |
| Q1 2016 | -21.91% |